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In this issue Matsumoto et al (2001) report the 10 year survival
rates of a randomized placebo-controlled trial in which colorectal
cancer patients received cimetidine and oral 5-ﬂuorouracil (5-
FU) or 5-FU alone as an adjuvant therapy following curative resec-
tion. In this small study a highly signiﬁcant improvement in
survival is demonstrated most notably in patients with node-posi-
tive (Dukes C) tumours (10 year survival – 85%). A further
retrospective analysis suggests that this appeared to be due to a
remarkable effect of cimetidine on patients with tumours expres-
sing the sialyl Lewis adhesion epitopes X and A (sL
x and sL
A).
The histamine type 2 (H2) receptor antagonist cimetidine was
ﬁrst proposed as an anti-cancer agent in 1979 (Armitage and
Sidner, 1979). This followed the spontaneous remission of two
patients with metastatic carcinoma after coincidental use of the
drug. Since then there have been several clinical trials assessing
cimetidine in a range of malignancies with varied and inconclusive
results.
In 1988 it was reported that post-operative treatment with cime-
tidine improved survival in gastric cancer patients of all stages
(increasing median survival from 316 to 459 days) (Tonnesen et
al, 1988). However, in a more recent and larger study organized
by the British Stomach Cancer Group, cimetidine had no effect
on survival when compared to placebo (Langman et al, 1999).
Trials combining cimetidine with immunotherapy approaches in
renal cell carcinoma and melanoma have also failed to demonstrate
any beneﬁt to the addition of cimetidine (Creagan et al, 1985;
Sagaster et al, 1995).
Results have been more promising using cimetidine in colorec-
tal cancer. In addition to the study in this issue (which was ﬁrst
reported in 1995; Matsumoto, 1995), there are now three other
studies that have shown non-signiﬁcant trends to improved survi-
val. In 1994 Adams and Morris reported that a 7 day
perioperative course of cimetidine improved 3-year survival from
59 to 93% (P=0.17) in 34 colorectal cancer patients (Adams and
Morris, 1994). In a more recent study of 125 patients by the same
group this regime showed a similar trend that achieved signiﬁ-
cance in patients with tumours negative for microsatellite
instability (Kelly et al, 1999). In a randomized study of 192
patients, Svendsen et al (1995) also showed a trend to improved
survival in Dukes C patients. In addition to these studies of adju-
vant cimetidine, a small trial compared 5-FU-based chemotherapy
alone or in combination with cimetidine in patients with advance
disease (Links et al, 1995). Although no difference in overall
response was seen there was a signiﬁcantly increased rate of
CEA response (450% reduction compared with baseline) in the
cimetidine group.
The exact mechanism by which cimetidine may exert an anti-
cancer effect remains uncertain. High concentrations of histamine
are known to occur in colorectal cancer tissues (Garcia-Caballero
et al, 1993). Histamine stimulates the in vivo growth of experimen-
tal colorectal tumours and cimetidine can inhibit this effect
(Adams et al, 1994a). However, other, far more potent H2 receptor
antagonists such as ranitidine do not show the same effect either in
vitro (Lawson et al, 1996), or in large clinical trials (Nielsen et al,
1998). This suggests that either the H2 receptor on tumour cells is
structurally distinct from those found on parietal cells, or that the
mechanism of action my be independent of classical H2 receptor
antagonism.
Cimetidine has also been shown to have a number of immuno-
modulatory effect. Histamine negatively regulates T helper (TH1
and TH2) cell responses through the H2 receptor and H2 receptor
knockout mice show upregulation of TH1 and TH2 cytokines (Jutel
et al, 2001). Increased release of histamine has been proposed as
the cause of the immunosuppression seen at the time of colonic
resection and several studies have shown that perioperative H2
receptor antagonists can prevent this effect, thereby improving
immune surveillance at the time of surgery (Adams et al, 1994b).
The presence of tumour inﬁltrating lymphocytes (TIL) within
rectal tumour tissues is considered to be an independent patholo-
gical marker of good prognosis (Harrison et al, 1994). Early clinical
studies suggested that perioperative treatment with cimetidine
resulted in an increased peritumoural lymphocyte inﬁltration
(Adams and Morris, 1994, 1997). A more recent trial however,
has failed to conﬁrm this with the subgroup of patients appearing
to beneﬁt most from cimetidine being the aggressive tumours that
lacked TILs (Kelly et al, 1999).
Recently Kobayashi et al (2000) have proposed a novel mechan-
ism of action. They showed that cimetidine could block the
adhesion of a colorectal tumour cell line to endothelial cells in vitro
and could suppress the formation of hepatic metastases in a nude
mouse model, via the down regulation of cell surface expression of
the adhesion molecule E-selectin on endothelial cells.
E-selectin (or ELAM-1) is a member of the selectin family of
adhesion molecules. Expression of E-selectin is induced on the
cell surface of activated endothelial cells by key mediators of
inﬂammation such as Il-1b and TNF-a (Bevilacqua et al, 1987)
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through the carbohydrate ligands sL
X and sL
A which are
expressed predominantly on neutrophils (Phillips et al, 1990).
In this way neutrophils can be recruited to sites of inﬂammation.
However, sL
X and sL
A are known to also be expressed on a
number of different tumour cell types and for many years this
interaction has been implicated in the pathogenesis of cancer
metastasis (Brodt et al, 1997; Dennis et al, 1982; Kitayama et
al, 2000). SL
X expression is increased in human hepatic colorec-
tal metastases compared to the primary tumour (Hoff et al,
1989) and expression has been shown to correlate with poor
survival of colorectal cancer patients (for example, in stage III
patients 5 year survival was 42% in the sL
X positive group vs
81% in patients with tumours negative for sL
X in one study)
(Nakamori et al, 1993). Expression of E-selectin on endothelial
cells has also recently been shown to be essential in models of
transendothelial migration of colon carcinoma cells (Laferriere
et al, 2001).
Matsumoto et al (2001) have also retrospectively analyzed the
patients in their previous study of cimetidine in colorectal cancer
according to sL
A and sL
X expression. This was a small study the
primary endpoints of which were originally to improve appetite
and reduce oesophagitis, not prolong survival. In addition, it has
not been analyzed on an intention to treat basis (10% of patients
were excluded from analysis). The results, however, are striking
and do appear to justify further investigation of the effect of cime-
tidine on E-selectin expression and the consequences of this
interaction on sL
A and sL
X expressing colonic carcinoma.
In summary, there appears to be beneﬁcial effects of cimetidine
on colorectal cancer. There is some evidence for immunological
mechanisms and for effects on E-selectin mediated adhesion.
Further large-scale clinical trials appear warranted.
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